Inhaled corticosteroids and asthma control in adult-onset asthma: 12-year follow-up study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
12-year adherence to inhaled corticosteroids in adult-onset asthma Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
12-year adherence to inhaled corticosteroids in adult-onset asthma Source: ERJ Open Res, 6 (1) 00324-2019; 10.1183/23120541.00324-2019 Year: 2020
The treatment with flunisolide in severe steroid asthmatics: the three-year follow-up study Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001
Predictors of adherence to inhaled corticosteroids in children with asthma and their parents in a multi-ethnic population Source: Annual Congress 2007 - Education, communication and quality of life in childhood asthma Year: 2007
Effectiveness of early intervention with budesonide in mild persistent asthma — 5-year data from the START study Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study Source: Eur Respir J, 54 (6) 1900901; 10.1183/13993003.00901-2019 Year: 2019
Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006–2016 Source: Eur Respir J, 53 (4) 1802130; 10.1183/13993003.02130-2018 Year: 2019
Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007
Meta-analysis of inhaled corticosteroids response in children with asthma. Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics Year: 2019
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011
Three-year prospective cohort study of growth in asthmatic children prescribed appropriate inhaled corticosteroid (ICS) doses Source: Eur Respir J 2004; 24: Suppl. 48, 614s Year: 2004
Long-term adherence to inhaled corticosteroids and asthma control in adult-onset asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018
Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Asthma control and medication use five years after early or delayed introduction of inhaled corticosteroids in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013